An international Phase II randomized double-blinded, placebo-controlled, mulit-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients wiht unresectable locally advanced or metastatic medullary thyroid cancer

Grants and Contracts Details

StatusFinished
Effective start/end date4/3/07 → 3/31/16

Funding

  • AstraZeneca Pharmaceuticals AB: $203,566.00